hotspot -WSS

hotspot

author：entertainment 2025-09-05 09:20:12 - browse：27

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Change Healthcare cyberattack outage could last weeks

knowledge

WSS

RSV vaccines may be linked to small increased risk of developing GBS

RSV shot was 90% effective at preventing hospitalizations in kids

Pfizer highlights cancer drugs it thinks could reignite investor interest

FDA does about

Precocious puberty in girls comes with mental health risks

Flu vaccine offering decent levels of protection this winter, new data show

entertainment

hotspot

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Air quality improving but still lags in Black, Hispanic communities

Peter Hotez and the public health issue of online harassment

Sen. Paul opposes bill to ban Chinese biotechs

Medicare proposal to cover medical devices draws a mixed reaction

How to fix the rural physician shortage in the U.S.

State Dept. review finds Biden bears some blame for Afghanistan failures

In his State of the Union, Biden takes clear aim at 'Big Pharma'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Air quality improving but still lags in Black, Hispanic communities

Wikipedia

House looks to weaken Medicare negotiation

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

An inside look at PIPEs, biotech's buzzy new financing tool

Obesity now affects over 1 billion people worldwide, study finds

FogPharma raises $145 million in rare Series E round

Headspace, Meta partner to launch VR meditation app for Quest

knowledge

explore

focus

focus